Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 27% no CI Improvement Relative Risk Death/ICU 38% no CI Mortality (b) 33% no CI Mortality (c) 44% no CI c19ivermectin.com La Pampa et al. Ivermectin for COVID-19 EARLY Favors ivermectin Favors control
La Pampa, 21,418 patient ivermectin early treatment study: 27% lower mortality and 38% lower combined mortality/ICU admission https://c19p.org/lapampa
copied to clipboard
La Pampa expondrá a la comunidad científica los resultados del Programa de Intervención Monitoreado de Ivermectina
La Pampa, Argentina (News)
10 Aug 2021    Source   PDF   Share   Tweet
News report on the use of ivermectin in La Pampa, Argentina, showing lower mortality with treatment.
risk of death, 27.4% lower, RR 0.73, treatment 3,269, control 18,149.
risk of death/ICU, 38.0% lower, RR 0.62, treatment 3,269, control 18,149.
risk of death, 33.4% lower, RR 0.67, treatment 3,269, control 18,149, >40yo.
risk of death, 44.0% lower, RR 0.56, treatment 3,269, control 18,149, >40yo including comorbidities.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta analysis: minimal details provided.
La Pampa et al., 8/10/2021, retrospective, Argentina, South America, preprint, 1 author, dosage 600μg/kg days 1-5.
All Studies   Meta Analysis
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit